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The flexible fiberoptic bronchoscope was in-
troduced in Japan by Dr. Shigeto Ikeda in the mid-
l 960s and became available .for clinical use in the 
United States around i 970. The application of this 
technique represents one of the most significant ad-
vances for the diagnosis and management of chest 
diseases as it enables the physician to directly visual-
ize the tracheobronchial tree and obtain diagnostic 
specimens from regions of the lung previously in-
accessible to the rigid bronchoscope. Except for sub-
pleural lesions, fiberoptic bronchoscopy is the surgi-
cal procedure of choice in the evaluation of many 
pulmonary lesions.' In addition, fiberoptic bron-
choscopy plays a major therapeutic role in the evalu-
ation of airway patency and elimination of retained 
secretions. 
The new Olympus® (BF-IT), Machida® (FBS-
6TL; FBS-6TL II), and Pen tax® (FB- l 9A) fiberoptic 
bronchoscopes have larger channels measuring 2.6 
mm in diameter as compared with older inodels 
whose channels measure 1.8 to 2.2 mm. These larger 
channels provide more effective suctioning and larger 
biopsy specimens.2 
Indications for Fiberoptic Bronchoscopy 
The following are accepted indications for fiber-
optic bronchoscopy: 
1. Any pulmonary lesion of uncertain nature. 
Subpleural lesions are exceptions. 
2. Retained bronchial secretions 
3. Evaluation of airway patency 
4. Miscellaneous: 
a. hemoptysis in a patient with a normal 
chest radiograph 
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b. positive sputum cytology (that is, cancer) 
in a patient with normal chest radiograph 
c. small, peripheral foreign bodies in adults 
d. patients with trauma or disease affecting 
the cervical spine or jaw 
e. patients on mechanical ventilators 
Rigid bronchoscopy is preferred in the following 
situations: 
1. Severe pulmonary hemorrhage 
2. Centrally located foreign bodies 
3. Children requiring bronchoscopy 
4. Tracheal stenosis, secondary to intrinsic or 
extrinsic lesions 
Risks and Contraindications 
The following conditions are associated with in-
creased risks during or following fiberoptic bron-
choscopy:3 
1. Hemoptysis (increased incidence of post-
bronchoscopy bleeding) 
2. Bronchial asthma (danger of severe bron-
chospasm) 
3. Uremia ( danger of severe hemorrhage after 
biopsy) 
4. Immunosuppression (hazard of post-bron-
choscopy infection) 
5. Superior vena cava obstruction ( danger of 
inducing laryngeal edema) 
Poor patient cooperation, hypoxemia with an 
arterial Po2 that cannot be increased to 60 to 65 torr 
with supplemental oxygen, uncorrected bleeding dia-
thesis, acute respiratory acidosis of any degree, dan-
gerous cardiac arrhythmias, recent (within six weeks) 
acute myocardial infarction, and untreated active 
pulmonary tuberculosis are contraindications for fi-
beroptic bronchoscopy. Terminally ill and aged pa-
tients with unstable vital signs should not have fiber-
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optic bronchoscopy performed. Severe pulmonary 
hypertension and poor cardiopulmonary reserve are 
relative contraindications. 
Physician and Patient Preparations for Fiberoptic 
Bronchoscopy 
Prior to bronchoscopy, the endoscopist should 
perform a history and physical examination, review 
the chest radiographs, electrocardiograms, and blood 
and urine tests . Arterial blood gas and spirometric 
studies should be performed, if possible, prior to the 
procedure. Coagulation studies (prothrombin time, 
partial thromboplastin time, platelet count) should 
be obtained. Three sputum smears for acid-fast orga-
nisms shouid be obtained in patients whose chest 
radiographs are consistent with a diagnosis of tu, 
berculosis . Finally, a signed operative permit should 
be obtained from the patient. 
Oxygen prophylaxis. All patients should receive 
supplemental _,oxygen administered by nasal catheter 
or cannula 5 L/ min . The Pao2 may decrease as much 
as 20 torr during and for several hours after bron-
choscopy .4 This drop in oxygen tension appears to be 
the result of multiple factors , including partial or 
complete obstruction of the airways, filling of alveo-
lar spaces with lavage or anesthetic solutions, and 
suctioning. Therefore, all patients who have a re-
duced Pao2 prior to the procedure should be given 
supplemental oxygen for six to ten hours following 
bronchoscopy. 
Cardiac monitor. It is desirable that all patients 
should have cardiac monitoring during bron-
choscopy. The sudden development of an arrhythmia 
or change in cardiac rate may suggest hypoxemia. 
Recent studies suggest that fiberoptic bronchoscopy 
does not consistently enhance preexisting ectopic 
beats in patients with ischemic heart disease, there-
fore, the procedure is not contraindicated in patients 
with stable angina . However, patients with coronary 
heart disease should be monitored closely during the 
procedure, since sinus tachycardia can develop, 
which may cause ischemic events thus precipitating 
arrhythmias.• The most important factor in the devel-
opment of arrhythmias is not bronchoscopy itself, 
but rather the underlying cardiopulmonary status of 
the patient . 
Preoperative orders. For a morning procedure, 
NPO after midnight is required; for an afternoon 
procedure, only a light liquid breakfast may be given . 
Atropine 0.8 to 1.0 mg is given intramuscularly 30 
minutes before bronchoscopy since this drug blocks 
vasovagal reflexes and also reduces the amount of 
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bronchial secretions. Depending upon the age, size 
and clinical condition of the patient, morphine 7 .5 to 
15 mg or meperidine 50 to 100 mg may be given 
intramuscularly with the atropine. In our institution 
we commonly use codeine 60 mg and atropine 0.8 to 
1.0 mg 30 minutes prior to bronchoscopy. Patients 
with severely reduced pulmonary function are given 
only atropine. 
Topical anesthesia is an extremely important 
factor in securing patient acceptance and performing 
a successful bronchoscopic examination. Lidocaine is 
the most commonly used agent as it is effective and 
safe provided a maximum dosage of 600 mg is not 
exceeded during the procedure. This dose, which is 
larger than that usually recommended, has been 
found safe in a large series. In patients with severe 
liver disease or congestive heart failure no more than 
300 mg should be given. 
The patient is first instructed to gargle with ap-
proximately 4 ml of 4% lidocaine for one to two 
minutes, followed by spraying of the oropharynx and 
the most widely patent nostril with 5 ml of 4% lido-
caine via a #15 DeVilbus atomizer. Cotton balls 
soaked in 4% lidocaine are applied to each piriform 
sinus for one minute; then , via a curved cannula, 2.0 
ml of I% lidocaine is administered over the vocal 
cords. 
With the patient either seated or supine the flex: 
ible fiberoptic bronchoscope can be passed (with or 
without an endotracheal tube) either transnasally or 
transorally . The most commonly used technique for 
diagnostic study in the United States is the direct 
transnasal passage. (If fiberoptic bronchoscopy is 
carried out through an endotracheal tube, the inter-
nal diameter of the tube should be 8.5 mm). The 
distal six inches of the fiberoptic bronchoscope is 
lubricated with lidocaine jelly. The bronchoscope is 
then passed through the nostril and when in the 
oropharynx, the tip angulated anteriorly to view the 
larynx. If the patient begins coughing, 2 ml of 1 % 
lidocaine is administered over the vocal cords. The 
patient is instructed to take a deep breath, and the 
bronchoscope is passed into the trachea during this 
inspiration. Additional small amounts of I% lido-
caine are given as necessary to suppress coughing. 
Once the bronchoscope is in the tracheobronchial 
tree, examination of all five lobes can be performed in 
approximately 10 to 15 minutes . 
Biopsy Technique 
A variety of biopsy instruments, primarily 
brushes and forceps, are available for diagnosis of 
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pulmonary lesions. In general, both brushes and for-
ceps are used for all lesions. The brush biopsy is 
obtained by moving the brush briskly back and forth 
over the suspicious area. If the bronchoscope has 
been introduced through the endotracheal tube, after 
each biopsy, the brush is pulled back just inside the 
bronchoscope and the bronchoscope removed from 
the tracheobronchial tree. The brush is then ad-
vanced forward and smears are made on glass slides 
which are placed in 95% alcohol. 
Forceps biopsy can be used in the diagnosis of 
local or diffuse pulmonary lesions. In diffuse lung 
disease, the forceps is introduced into a small periph-
eral airway, usually in a lower lobe segment. The 
forceps is opened in inspiration, the patient is in-
structed to exhale completely, the forceps is advanced 
slowly about I cm, and at the end of an exhalation 
the biopsy obtained. Following the removal of the 
forceps, the distal end of the bronchoscope should be 
wedged into the bronchial segment for one minute to 
prevent possible bleeding. The biopsy specimen is 
placed in a sterile tube filled with Ringer solution. In 
general, three to four specimens, sometimes as many 
as six to eight, are taken . Bronchial washings with 10 
to 20 ml saline solution should also be obtained. The 
specimens should be sent for cytology, smears, a nd 
cultures for acid-fast organisms, fungi, and patho-
genic organisms. 
It is desirable to perform transbronchial biopsy 
under fluoroscopic control if available. Because of 
the possibility of bilateral pneumothorax, biopsies 
are taken from one lung only. 
In localized disease the forceps is introduced to 
the lung lesion, then withdrawn I cm, opened, then 
advanced until it touches the lesion; the forceps is 
closed and the biopsy obtained. Prior to brush or 
forceps biopsy, administration of 5 ml boluses of 
I: 20,000 epinephrine over visible tumors or into dis-
tal airways (in cases of diffuse lesions) before biopsy, 
reduces the incidence of pulmonary hemorrhage. A 
total of 20 ml of I: 20,000 epinephrine solution can be 
given over a period of 20 minutes, except in patients 
with severe hypertension and serious arrhythmias. In 
patients with uremia, brush or forceps biopsies 
should not be done because of the possibility of se-
vere hemorrhage; in those with a platelet count of less 
than 50,000/ mm,3 six to ten platelet packs should be 
infused just prior to bronchoscopy. Finally, patients 
with bronchial asthma are prone to develop severe 
bronchospasm. They should be given bronchodila-
tors and probably steroids prior to bronchoscopy. 
Where centrally located visible carcinoma of the 
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lung is present, the incidence of positive forceps 
biopsy is about 97%. The overall yield in peripheral 
carcinoma of the lung is about 60% to 70%, in meta-
static carcinoma of the lung, about 30% to 40%, and 
in diffuse lung diseases, the diagnostic yield ranges 
from 62% to 79%. In stage I sarcoidosis, trans-
bronchial biopsy will confirm the diagnosis in 50% to 
60% of cases while in stage II and stage III sarcoid-
osis, diagnostic success is about 90%. 
Complications of Fiberoptic Bronchoscopy 
The overall complication rate is approximately 
8%. The mortality rate is 0.1 %. The following are 
potential complications: 
I. Hypoxemia 
2. Laryngospasm 
3. Hemorrhage 
4. Pneumothorax 
5. Bronchospasm 
6. Cardiac arrhythmias and acute myocardial 
infarction 
7. Post-bronchoscopy infection 
8. Trauma due to endotracheal tube insertion 
9. Hypoventilation 
In summary, fiberoptic bronchoscopy is an ex-
tremely useful technique in the diagnosis and man-
agement of pulmonary diseases. It is quite safe and 
comfortable for the patient and it permits examina-
tion of airways previously inaccessible to the endo-
scopist. However, physicians must evaluate each pa-
tient carefully. The procedure should be performed 
by an experienced endoscopist who is familiar with 
risk factors and proper indications for fiberoptic 
bronchoscopy. 
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